Normal view MARC view ISBD view

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. - 2024

English

ISSN: 2041-1723

Standard No.: 10.1038/s41467-024-48359-1 [pii] PMC11087457 [pmc]

Subjects--Topical Terms: --Automated

Subjects--Geographic Terms:
MedStar Washington Hospital Center

Index Terms--Occupation:
Associate Dean for Research Development
Hematology/Oncology
MedStar Health

Index Terms--Function:
Published Erratum

Print
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)